Objects
Odelli, C., Burgess, D., Bateman, L., Hughes, A., Ackland, S., Gillies, J., Collins, C. E.. W. B. Saunders; 2005. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer.
Mercieca-Bebber, R., Barnes, E. H., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., Barbour, A. P., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D.. BioMed Central (BMC); 2022. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.
Denham, J. W., Steigler, A., Smithers, B. M., Ackland, S., Walpole, E., Kilmurray, J., Wratten, C., Burmeister, B., Lam, D. S., Joseph, D., Delaney, G., Christie, D., Jamieson, G.. The Royal College of Radiologists / Elsevier Science Ltd.; 2003. Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
Odelli, C., Burgess, D., Bateman, L., Hughes, A., Ackland, S., Gillies, J., Collins, C. E.. Elsevier; 2005. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer.
Odelli, C., Burgess, D., Bateman, L., Hughes, A., Ackland, S., Gillies, J., Collins, Clare E.. W.B. Saunders; 2005. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer.
Guo, S. T., Chi, M. N., Yan, X. G., Farrelly, M., Wang, F. H., Lai, F., Wang, J. F., Li, Y. P., Ackland, S., Scott, R., Agoulnik, I. U., Hondermarck, H., Yang, R. H., Thorne, R. F., Liu, T., Zhang, X. D., Jiang, C. C., Guo, X. Y., Zan, L. K., Wang, C. Y., Xi, Y. F., Jin, L., Croft, A., Tseng, H.-Y.. Nature Publishing Group; 2016. INPP4B is an oncogenic regulator in human colon cancer.